Working… Menu

Long Term Experience With Abatacept in Routine Clinical Practice (ACTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02109666
Recruitment Status : Completed
First Posted : April 10, 2014
Last Update Posted : April 19, 2017
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to estimate the retention rate of Abatacept over 24 months in routine clinical practice in every participating country depending on the treatment line.

Condition or disease Intervention/treatment
Rheumatoid Arthritis Drug: Abatacept

Detailed Description:

Time Perspective: Other: Collection of the baseline data collected at Abatacept IV initiation, prospectively or retrospectively within maximum 3 months following the first administration. Other assessments are collected during the follow up period (maximum of 2 years by patient)

Biospecimen Retention: None Retained excepted for a local sub study (in Spain) where sample with DNA was retained

Layout table for study information
Study Type : Observational
Actual Enrollment : 2364 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Long Term Experience With Abatacept in Routine Clinical Practice
Study Start Date : March 2008
Actual Primary Completion Date : February 2016
Actual Study Completion Date : February 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arthritis
Drug Information available for: Abatacept

Group/Cohort Intervention/treatment
RA patients treated with Abatacept
RA patients are treated with Abatacept IV according Summary of Product Characteristics (SmPC) in Europe and Product Monograph in Canada
Drug: Abatacept
Other Name: Orencia

Primary Outcome Measures :
  1. Retention rate of Rheumatoid arthritis (RA) patients treated with Abatacept in routine clinical practice [ Time Frame: Up to 24 months ]

Secondary Outcome Measures :
  1. Major determinants of treatment discontinuation of RA patients treated with Abatacept [ Time Frame: Up to 24 months ]
    Major determinants including prior RA treatment experience with biologics and clinical outcomes, such as Disease Activity Score 28 (DAS28), Health Assessment Questionnaire-Disability Index (HAQ-DI), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and their derived criteria

  2. Distribution of time-to-discontinuation of Abatacept therapy for each major determinant of treatment discontinuation, overall and depending on the treatment line [ Time Frame: Up to 24 months ]
  3. Association of prior RA treatment experience and clinical outcomes during the treatment course with patient reported outcomes (Patient satisfaction, Pain, Patient's Global Assessment) [ Time Frame: Up to 24 months ]
  4. Summary of treatment experience and outcomes after switching to a biologic or conventional Disease Modifying Anti-Rheumatic Drugs (DMARD) for patients who discontinue Abatacept therapy [ Time Frame: Up to 24 months ]

Biospecimen Retention:   None Retained
Whole blood (Spanish sub study only)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Crohn's Disease

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • Male or Female subjects of more than 18 years old
  • Patients with a diagnosis of established moderate to severe active RA (as per the American College of Rheumatology revised criteria, 1987), who at their physician's discretion are treated with Abatacept according to the SmPC in Europe and the Product Monograph in Canada (initiating or already on treatment for maximum 3 months) and for whom baseline characteristics are available

Exclusion Criteria:

  • Patients who are currently included in any interventional clinical trial in RA

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02109666

Layout table for location information
Local Institution
Salzburg, Austria, 5020
Local Institution
Gent, Belgium, 9000
Canada, Newfoundland and Labrador
Local Institution
St. John's, Newfoundland and Labrador, Canada, A1B3E1
Czech Republic
Local Institution
Prague 2, Czech Republic, 128 50
Local Institution
Holbaek, Denmark, 4300
Local Institution
Montpellier, France, 34295
Local Institution
Heidelberg, Germany, 64120
Local Institution
Crete, Greece, 71 201
Local Institution
Dublin, Ireland, 4
Local Institution
Siena, Italy, 53100
Local Institution
Amsterdam, Netherlands, 1056 AB
Local Institution
Sevilla, Spain, 41071
Local Institution
Basel, Switzerland, 4055
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb Identifier: NCT02109666    
Other Study ID Numbers: IM101-151
First Posted: April 10, 2014    Key Record Dates
Last Update Posted: April 19, 2017
Last Verified: February 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents